C4 Therapeutics (CCCC) Cash & Current Investments (2019 - 2026)

C4 Therapeutics' Cash & Current Investments history runs 8 years deep, the most recent figure standing at $235.7 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 40.92% year-over-year to $235.7 million in Q1 2026; TTM through Mar 2026 was $235.7 million, a 40.92% increase from a year earlier, with the FY2025 full-year figure at $248.5 million, up 1.48% from the prior year.
• Cash & Current Investments eased to $235.7 million in Q1 2026 per CCCC's latest filing, from $248.5 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $307.8 million in Q2 2022 and bottomed at $130.5 million in Q4 2023.
• The 5-year median for Cash & Current Investments is $235.7 million (2026), against an average of $221.6 million.
• Across the five-year window, Cash & Current Investments sank 47.72% in 2023 and jumped 87.62% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $249.7 million in 2022, then sank by 47.72% to $130.5 million in 2023, then soared by 87.62% to $244.9 million in 2024, then climbed by 1.48% to $248.5 million in 2025, then decreased by 5.18% to $235.7 million in 2026.
• Per Business Quant, the three latest CCCC Cash & Current Investments figures stand at $235.7 million (Q1 2026), $248.5 million (Q4 2025), and $136.5 million (Q3 2025).